Merck & Co's second-quarter profits drop by 12% - update
This article was originally published in Scrip
Merck & Co's second-quarter net income fell by 12%, hit by negative currency effects and poor sales of its cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe plus simvastatin).
You may also be interested in...
Just as the MDR and IVDR are being implemented, increasing regulatory divergence in Europe is a growing danger to patient safety throughout the EU, not least through increasing costs and impacting device availability.
Swiss biotech Molecular Partners will receive upfront payment of CHF 60m, including equity.
It’s time to focus on how the diagnostics sector will comply with the EU’s IVD Regulation. TÜV SÜD expert, Andreas Stange, explains why the IVD industry could be in trouble and what must be done now.